English Abstract
Journal Article
Research Support, Non-U.S. Gov't
Add like
Add dislike
Add to saved papers

[Insulin-like growth factor receptor I signaling in a breast cancer cell line].

INTRODUCTION: In vitro studies strongly suggest that proliferation, migration and cell survival of breast cancer cell lines are significantly affected by activation of the IGF type 1 receptor (IGF-IR).

OBJECTIVE: The phosphorylation by IGF-I of IGF-IR and the intracellular signaling molecules Akt (PI-3K pathway) and Erk1/2 (MAPK pathway) was characterized in a human breast cancer cell lines.

MATERIALS AND METHODS: The study compared a standard breast adenocarcinoma line (MCF-7) cell line with a line (CSC 1595) derived from an infiltrating ductal breast cancer in a Colombian patient. The CSC 1595 and MCF-7 cell lines were cultured in DMEM supplemented with 10% fetal bovine serum, 2 mM glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin and grown at 37 °C in 5% CO₂ atmosphere and 95% humidity. Cell extracts were prepared, followed by immunoprecipitation and immunoblotting with specific anti-pIGF-IR, anti-pERK1/2 and anti-pAkt antibodies.

RESULTS: After 5 minute stimulation with IGF-I, 70% of the IGF-IR was phosphorylated in the cell line CSC 1595 and 25% in MCF-7. In addition, Akt (oncogene protein v-akt) and ERK1/2 (extracellular signal-regulated MAP kinases) were phosphorylated. Basal and stimulated levels of phosphorylated ERK1/2 were substantially higher compared to those in the MCF-7 cell line.

CONCLUSIONS: The IGF-IR and MAPK kinase pathway involving proteins ERK1/2 showed more significant phosphorylation in the 1,595 cells compared to the observed in the MCF-7 cell line. Since the IGF-IR is the major activator of this pathway it may play an important role in ductal infiltrating breast cancer tumor growth and metastases.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app